REGN240927P1100000
- 55.70
- -23.80-29.94%
Regeneron Pharmaceuticals Newsroom
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,247
Trending Stocks Today | TELESIS BIO Shoots up 124.13% Post-Market
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,245
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron Pharma Price Target Maintained With a $1300.00/Share by BMO Capital
Regeneron Pharmaceuticals Worst Performer in the S&P 500 and Nasdaq 100 So Far Today -- Data Talk
Regeneron Pharmaceuticals Hits 7-week Low
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,250
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Regeneron Downgraded at Leerink After Amgen's Court Win; Truist Defends
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,200 to $1,300
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday